Headline: NHS Rejects Alzheimer's Drug Lecanemab Over Cost Concerns Despite Approval Elsewhere
Caption:
The NHS in England will not offer the first drug to slow early-stage Alzheimer's, Lecanemab, due to concerns that the benefits do not justify its high costs, according to NICE (National Institute for Health and Care Excellence), BBC News reports. Lecanemab, approved by the UK's MHRA, is available privately but not on the NHS; the drug slows cognitive decline by about 25% over 18 months
Keywords: NHS,Rejects,Alzheimer,Drug,Lecanemab,Over,Cost,Concerns,Despite,Approval,Elsewhere,Japan,UK,National Institute for Health and Care Excellence,NICE,England,Hospitals,Patients,Restrictions,Brain,Protein,Risks,Benefits,China,US,PET Brain Scans,Lumbar Punctures
PersonInImage: